戻る Agenda
Session 6: Payer Market Dynamics
Session Chair(s)
Stanton Mehr
Director of Content
Biosimilars Review and Report, United States
Over the next 24 months, the biosimilar industry will be entering a crucial phase in the US. Payers have played a leading role in determining whether biosimilars are covered and influencing their uptake. This session will address how payers are considering anticipated biosimilar launches for adalimumab, insulin, and ranibizumab.
Learning Objective : At the conclusion of this session, participants should be able to:
- Describe the factors that payers may consider when deciding which adalimumab biosimilar(s) or the reference product they will place on formulary
- Recognize the benefits or risks that covering a biosimilar under the pharmacy benefit (vs the medical benefit) can pose for payers
- Assess how payers will approach potential interchangeability designations among these critical biosimilar categories
Speaker(s)
Preparing for Humira Biosimilars
Luke Greenwalt, MBA
IQVIA, United States
Vice President, Market Access, Center of Excellence
Payer Aspects: What It Would Mean to Cover Biosimilars Under the Pharmacy vs. Medical Benefit
James Kenney, MBA, RPh
JTKenney, LLC, United States
Principal
The Potential Impact on Payers of Biosimilar Insulin
Stephanie L. Ho, PharmD
Kaiser Permanente, United States
Pharmacist Evidence Analyst and Strategist
Improving Hospital and Health System Uptake of Biosimilars
Steven Lucio, PharmD
Vizient Inc., United States
Senior Principal, Center for Pharmacy Practice Excellence